In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress
6 July 2020 Global biotherapeutics leader CSL Behring today announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe…
ANDHealth releases the first detailed report on Australia’s digital health industry
3 July 2020 Three years in the making, ANDHealth are proud to bring you a brand new report – Digital Health: The Sleeping Giant of Australia’s Health Technology Industry. Packed with data and information we’ve collected from the…
KPMG – The Digital Delta Innovation Trends Survey 2020
3 July 2020 Business leaders in recent years have consistently indicated that innovation is amongst their top priorities. KPMG want to help you better understand how your Australian peers’ innovation perspectives and actions are changing, as we adjust…
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
30 June 2020 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434…
Acrux announces co-development agreement with Amring Pharmaceuticals Inc
2 July 2020 Acrux Limited a commercial-stage pharmaceutical company focused on developing generic topical drug products is pleased to announce that it has entered into an exclusive development and commercialisation agreement with Amring Pharmaceuticals, Inc. in the United…
Almac Group Launches Tempod 1000 to Improve Clinical Site Temperature Data Management
24 June 2020 Almac Clinical Services, part of the Almac Group, the global contract pharmaceutical development and manufacturing organization, has launched Tempod® 1000 which bolsters the company’s Site Compliance and temperature management offering for sponsors. An extension to Almac’s…
AAMRI’s new animation shows the speed and breadth of COVID-19 research happening across Australia
29 June 2020 When Australia first heard about COVID-19, very few of us understood how completely it would change our day to day lives – including at our medical research institutes. Today the Association of Australian Medical Research…
New c-FIND test accurately diagnoses infection in minutes
1 July 2020 Walter and Eliza Hall Institute researchers have developed a fast, new test for infections and infectious diseases that could transform Australia’s ability to provide targeted clinical care and respond to pandemics and biosecurity threats. Called…
Phillips Ormonde Fitzpatrick reappointed to IP panel for CSIRO
1 July 2020 The Phillips Ormonde Fitzpatrick (POF) Group are pleased to announce reappointment as a preferred IP provider for CSIRO, Australia’s leading national science and technology organisation. POF has worked with CSIRO for over 40 years and…
Investment In Artificial Intelligence Is Real Deal For Victoria
26 June 2020 The Victorian Government today announced it would contribute $1.5 million to the establishment of Australia’s first multimillion-dollar accelerator and investment fund for Artificial Intelligence (AI) scaleups. Backed by LaunchVic, Victoria’s startup agency, Boab AI in…
$19 million for Artificial Intelligence health research projects
29 June 2020 The Morrison Government is investing $19 million in transformative medical research projects using game-changing applied artificial intelligence (AI) technologies, to improve the ways we prevent, diagnose and treat a wide range of health conditions. The…
Immutep Completes Recruitment For Part A Of Phase II TACTI-002 Study
29 June 2020 Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part A (1st line…
